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Background: High serum calcium levels should be avoided in patients on hemodialysis (HD) because they can
induce cardiovascular diseases and worsen the patient’s prognosis. In contrast, low serum calcium levels worsen the
prognosis of patients with cerebral hemorrhage in the general population. So far, whether serum calcium levels in
patients on HD are associated with cerebral hemorrhage remains unknown. This study aimed to reveal the
association between serum calcium and cerebral hemorrhage in patients on HD, including in-hospital death,
volume of hematoma, and onset of cerebral hemorrhage.
Methods: This cross-sectional case-control study included 99 patients on HD with cerebral hemorrhage at a single
center between July 1, 2007 and December 31, 2017. Controls included 339 patients on HD at a single HD center
between July 1, 2011 and June 30, 2012. Data on serum calcium level, patient demographics, and comorbid
conditions were collected, and associations between cerebral hemorrhage and subsequent death were evaluated
by multivariate logistic regression analysis. Further, the association of these backgrounds and hematoma volume
was evaluated by multiple regression analysis.
Results: Of the 99 patients, 32 (32%) died from cerebral hemorrhage. The corrected serum calcium level (odds ratio
[OR], 2.49; 95% confidence interval [CI], 1.43–4.35; P < 0.001) and antiplatelet drug use (OR, 3.95; 95% CI, 1.50–10.4;
P = 0.005) had significant effects on the prognosis. Moreover, the corrected serum calcium (P = 0.003) and
antiplatelet drug use (P = 0.01) were significantly correlated with hematoma volume. In the patients, the corrected
serum calcium level (OR, 1.54; 95% CI, 1.07–2.22; P = 0.02) was associated with the onset of cerebral hemorrhage, as
was pre-hemodialysis systolic blood pressure (per 10 mmHg) (OR, 1.40; 95% CI, 1.23–1.59; P < 0.001).
Conclusions: Although the precise mechanisms remain unknown, a high serum calcium level is associated with
cerebral hemorrhage in patients on HD. Thus, we should pay attentions to a patient’s calcium level.
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Stroke is a major cause of death and the leading cause of
disability in patients on hemodialysis (HD) worldwide,
where its incidence is several times higher than in the gen-
eral population [1–6]. Although the recent incidence of
cerebral infarction was found to be higher than that of cere-
bral hemorrhage in patients on HD [7], cerebral hemorrhage
had a greater impact on patients’ prognoses compared with
cerebral infarction [4, 6, 8]. To prevent cerebral hemorrhage
or mitigate the severity of cerebral hemorrhage, modifiable
factors in patients on HD are crucial.
Several traditional risk factors for cerebral hemorrhage
in patients on HD have been elucidated, such as male
sex [9], absence of antihypertensive drug [10], pre-
dialysis hypertension [2, 3, 5, 7, 9], low KT/V [3], and
high blood hemoglobin [11]. In addition to chronic kid-
ney disease (CKD)-mineral bone disorder, a high serum
phosphate level [9] and high intact parathyroid hormone
(iPTH) level [12] are known risk factors for cerebral
hemorrhage in patients on HD.
Since multiple studies have reported that a high calcium
concentration is associated with cardiovascular diseases
and a poor prognosis in patients with CKD [13–15], the
KDIGO guidelines have changed the recommendations
for avoiding hypercalcemia in patients on HD, although
the treatment range of serum calcium has been left un-
changed [16, 17].
In contrast, studies that were not restricted to patients
with end-stage renal disease (ESRD) have demonstrated
that a low serum calcium level worsens patients’ progno-
ses and enlarges the hematoma volume in acute cerebral
hemorrhage [18–20].
We decided to investigate the contradicting content of
whether serum calcium levels in HD patients with cere-
bral hemorrhage affect patients’ prognosis or onset. This
study aimed to reveal the association between serum cal-
cium and cerebral hemorrhage in patients on HD, in-
cluding in-hospital death, volume of hematoma, and
onset of cerebral hemorrhage.
Methods
Study design
This is a cross-sectional case-control study in the same
medical zone. The cases were of patients on HD with
cerebral hemorrhage who were admitted to Nagasaki
University Hospital or of patients on HD who developed
cerebral hemorrhage at Nagasaki University Hospital
during their stay for other treatments, but patients with
traumatic hemorrhage, subarachnoid hemorrhage, and
hemorrhage after ischemic stroke were excluded. The study
period was between July 1, 2007, and December 31, 2017.
Patients were diagnosed with cerebral hemorrhage using
computed tomography (CT) at Nagasaki University Hos-
pital within 3 days of experiencing neurological symptoms.Cases of traumatic hemorrhage were excluded based on the
decision of the neurosurgeons of our hospital and imaging
diagnosis at admission. Treatment strategies were discussed
by multiple neurosurgeons and neurologists. The controls
included patients who underwent HD between July 1, 2011,
and June 30, 2012, in Nagasaki Renal Center, which is the
largest HD facility in Nagasaki City. Almost a quarter of pa-
tients on HD at Nagasaki City medical zone were enrolled.
Patients who did not undergo HD in their birth month
were excluded because data collected in the birth month
and on birthdays were considered substituted events.
Data collection
Baseline characteristics of patients were collected
through a retrospective review of hospital medical re-
cords and medical referral letters. In addition, data on
the HD status just before admission, activities of daily
living (ADL) before onset, and medications as well as la-
boratory data obtained closest to the event were col-
lected from the medical referral letters. The hematoma
volume was determined from a CT scan on admission or
just after onset by a simplified formula as follows: max-
imum transverse diameter × maximal anteroposterior
diameter × maximal superoinferior diameter × 1/2 [3, 21],
which was natural-log transformed as in a previous study
[22]. The onset of time was estimated from medical refer-
ral letters; if it was impossible, we assigned noon as the
time of onset, as in previous reports [23]. The Glasgow
Coma Scale (GCS) score, National Institutes of Health
Stroke Scale (NIHSS) score [24], and severity of cerebral
hemorrhage were defined by ADL at discharge, which was
evaluated by the modified Rankin scale (mRS) [25], as fol-
lows: 0, no symptoms at all; 1, no significant disability des-
pite symptoms; 2, slight disability; 3, moderate disability
(able to walk without assistance); 4, moderately severe dis-
ability; 5, severe disability (bed ridden); and 6, death.
For the controls (control group), data were collected
from the medical records of Nagasaki Renal Center.
Similar to that in patients with cerebral hemorrhage
(cerebral hemorrhage group), data were collected in the
period before the patient’s birthday. The corrected
serum calcium levels were obtained using the Payne
equation [26]. A ratio of 1:200 was applied to convert
the darbepoetin-alfa and epoetin-beta pegol doses to
their equivalent epoetin doses [27].
Statistical analysis
Categorical variables were expressed as number (%),
whereas continuous values were expressed as mean ±
standard deviations (SD). Non-normally distributed data
were presented as median values with interquartile
ranges. Statistical analyses were performed using JMP 13
software (SAS Institute Inc., NC, USA). Wilcoxon rank
sum test and the chi-squared test were used to evaluate
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hemorrhage were divided into four groups (Q1–Q4)
with the cutoff values being the 25th, 50th, and 75th
percentiles of the corrected serum calcium levels. Ana-
lysis of variance and Cochran-Armitage test were used
to demonstrate the trend. Univariate and multivariate lo-
gistic regression analyses were also performed.
In the multivariate logistic regression analyses for the
prognosis of cerebral hemorrhage patients, model 1 was
only adjusted for age and sex, and parameters of model 2
were determined using a stepwise model (mixed method)
with an inclusion criterion of P < 0.1 in univariate logistic
regression analysis in addition to the corrected serum cal-
cium level. In the comparison of the cerebral hemorrhagea
b
Fig. 1 Patient flow diagram. a Patients with cerebral hemorrhage in Nagas
between July 1, 2011 and June 2012group and control group, model 1 adopted the risk factors
of traditional cerebral hemorrhage, including dialysis vin-
tage, history of diabetes, systolic blood pressure at initi-
ation of HD proximal to onset, hemoglobin, phosphate,
iPTH, and corrected serum-calcium. In model 2, parame-
ters were determined using a stepwise model (mixed
method) as described above.
Multiple regression analysis was performed to predict
hematoma volume. The constitutional parameters were
age, sex, and those associated with hematoma volume,
such as systolic blood pressure (sBP) pre-HD [3] and
corrected serum calcium levels [18, 20], and residual pa-
rameters were selected using the stepwise method
(mixed method). An inclusion criterion of P < 0.1 in theaki University Hospital. b Control patients in the Nagasaki Renal Center
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odds ratios (ORs) and 95% confidence intervals (CIs)
were calculated. A P value < 0.05 was considered statisti-
cally significant.
Past histories were excluded as constitutional parame-
ters in comparisons of the cases and controls because of
unavoidable information bias due to the differences in
data collection methods. Missing data were removed
from the analyses, and the remaining data were used.
Ethical consideration
All procedures involving human participants were per-
formed in accordance with the ethical standards of the
institutional review board (IRB) of Nagasaki University
Hospital (1602221–2) and Nagasaki Renal Center (Naga-
saki, Japan) (30001) and of the 1964 Declaration of
Helsinki and its later amendments. Although all patients
in this study were informed of the investigations being
performed, the study was a medical record-based retro-
spective analysis and the included patients were anon-
ymized. Therefore, the IRB approved the exemption
from obtaining written informed consent.
Results
Demographic data for patients with cerebral hemorrhage
The participants included 96 HD patients with cerebral
hemorrhage who were admitted to Nagasaki University
Hospital between 2007 and 2017 and 3 HD patients who
developed cerebral hemorrhage in the hospital. The pa-
tient flow diagram is shown in Fig. 1. The severity of
hemorrhage in terms of GCS, NIHSS, hematoma volume
at admission, and mRS at discharge is shown in Table 1.
The average age was 64.8 ± 10.7 years (men, 66; women, 33),
and the median dialysis vintage was 87months (Table 2).
The median date of the onset of cerebral hemorrhage was
May 21, 2012. Figure 2a shows hemorrhagic areas, andTable 1 Cerebral hemorrhage patients’ condition on admission
Total (N = 99)
Features of cerebral hemorrhage
sBP on admission (mmHg) 184 ± 34
dBP on admission (mmHg) 96 ± 23
Pulse pressure on admission (mmHg) 80 ± 18
Glasgow Coma Scale 10 ± 4
NIHSS 15 ± 10
Intraventricular hemorrhage (%) 64
Volume of hematoma (mL) 50 ± 60
Surgical hematoma evacuation (%) 31
Onset during 2-day interval HD (%) 37
Time for patients to transport (hour)a 4 (3–12)
dBP diastolic blood pressure, HD hemodialysis, NIHSS National Institute of Health St
Continuous variables are shown as mean ± standard deviation and categorical varia
a Median (interquartile range)Fig. 2b shows the distribution of the hematoma volume. Se-
vere outcomes were observed in 66 patients (67%): 32 died
(mRS: 6) and 34 were severely disabled (mRS: 5). Figure 2c
shows the total mRS score at discharge.
Significant differences were observed in the GCS,
NIHSS, intraventricular hemorrhage, and volume of
hematoma between patients who died and those who
survived (Table 1).
Characteristics of HD patients with cerebral hemorrhage
and controls
Patients with cerebral hemorrhage and controls were
compared to clarify the correlations for the onset of
cerebral hemorrhage. The number of patients who
underwent HD in the Nagasaki Renal Center between
July 1, 2011, and June 30, 2012, was 402; however, 30
were excluded because of death or relocation to other
facilities before their birth month, and 33 were excluded
because of moving to our facility after their birth month.
Therefore, the number of control patients on HD was
339 (Fig. 1). Table 2 (right side) shows the demographic
data of patients with cerebral hemorrhage and the
controls.
Differences between patients who died and those who
survived following cerebral hemorrhage
Table 2 (left side) shows patients’ background data,
which were confirmed or examined during the pre-
critical stage, and the differences between patients
who died and those who survived. Significant differ-
ences were observed in the past histories of ischemic
heart disease and heart valve repair or replacement,
use of antiplatelet drugs and warfarin, and corrected
serum calcium levels.
According to a multivariate logistic analysis, corrected
serum calcium, antiplatelet use, and heart valve repair orDied (N = 32) Survived (N = 67) P value
187 ± 36 183 ± 33 0.7
100 ± 25 94 ± 22 0.3
81 ± 24 80 ± 15 0.9
6 ± 3 12 ± 4 < 0.001
23 ± 9 11 ± 9 < 0.001
97 48 < 0.001
103 ± 70 24 ± 33 < 0.001
34 30 0.7
41 36 0.6
6 (3–12) 4 (3–11) 0.4
roke Scale, sBP systolic blood pressure
bles, as percentage or number (percentage)
Table 2 Demographic data of patients with cerebral hemorrhage divided by dead or alive and control patients
Died (N = 32) Survived (N = 67) P value CH all (N = 99) Control (N = 339) P value
Age (year) 64.9 ± 9.2 64.7 ± 11.5 0.7 64.8 ± 10.7 67.4 ± 13.3 0.06
Male (%) 62.5 68.7 0.5 66.7 57.2 0.09
HD vintage (months)a 85 (30–169) 88 (27–177) 0.7 87 (29–177) 56 (23–122) 0.04
Cause of ESRD
Chronic glomerulonephritis (%) 28 48 41 38
Diabetes (%) 44 31 35 28
Nephrosclerosis (%) 13 7 9 17
ADPKD (%) 6 7 7 4
Others (%) 6 6 6 6
Unknown (%) 3 0 0.3 1 7 0.02
Past history
Diabetes mellitus (%) 44 37 0.5 39 35 0.4
Ischemic heart disease (%) 34 9 0.002 17 34 < 0.001
Atrial fibrillation (%) 3 12 0.11 9 10 0.8
Heart valve repair or replacement (%) 16 2 0.008 6 4 0.2
History of cerebral infarction (%) 31 34 0.8 33 25 0.09
History of cerebral hemorrhage (%) 16 13 0.8 14 6 0.02
Medication
Number of antihypertensive drugs 1.6 ± 1.2 1.9 ± 1.3 0.3 1.8 ± 1.3 1.6 ± 1.5 0.09
Antiplatelet use (%) 65 36 0.008 45 39 0.3
Warfarin use (%) 25 7 0.02 13 7 0.07
Statin use (%) 17 9 0.3 11 16 0.3
Vitamin D use (%) 54 66 0.3 62 67 0.1
Phosphate binder use (%) 71 68 0.8 69 65 0.5
CaCO3 use (%) 52 47 0.7 48 48 1.0
Cinacalcet use (%) 13 18 0.6 16 17 0.9
Walking independently (mRS≦3) (%) 77 86 0.2 83 80 0.5
Dialysis conditions
Dialyzing time (hr)a 4 (3–4) 4 (3.5–4) 0.7 4 (3.5–4) 4 (3–4) 0.02
Dry weight (kg) 52.4 ± 11.5 53.7 ± 11.5 0.4 53.3 ± 11.5 52.1 ± 11.0 0.3
Fluid removal per dry weight proximate to the onset (%) 3.14 ± 2.04 3.35 ± 1.71 0.6 3.29 ± 1.81 3.10 ± 1.74 0.3
Dialysate Ca concentration (mEq/L) 2.81 ± 0.14 2.79 ± 0.18 0.7 2.79 ± 0.17 2.75 NA
Online HDF (%) 13 7 0.4 9 22 0.002
sBP pre-HD proximate to the onset (mmHg) 167 ± 31 167 ± 22 1.0 167 ± 25 150 ± 24 < 0.001
dBP pre-HD proximate to the onset (mmHg) 86 ± 14 87 ± 16 0.8 87 ± 16 78 ± 13 < 0.001
Pulse pressure proximate to the onset (mmHg) 81 ± 24 80 ± 15 1.0 80 ± 18 72 ± 21 < 0.001
ESA (U/week) 6719 ± 3592 6296 ± 4556 0.6 6435 ± 4247 5513 ± 4396 0.03
Epoetin (%) 38 28 31 9
Darbepoetin (%) 41 37 38 47
CERA (%) 13 18 16 27
Intravenous iron use (%) 22 27 0.6 25 19 0.08
Laboratory parameters
Hb (g/dL) 10.6 ± 1.9 10.6 ± 1.5 0.4 10.6 ± 1.7 10.8 ± 1.4 0.09
Ferritin (ng/mL)a 139 (54–284) 71 (31–167) 0.095 85 (34–212) 53 (21–154) 0.03
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Table 2 Demographic data of patients with cerebral hemorrhage divided by dead or alive and control patients (Continued)
Died (N = 32) Survived (N = 67) P value CH all (N = 99) Control (N = 339) P value
TSAT (%) 21.3 ± 11.3 24.4 ± 12.9 0.4 23.4 ± 12.4 24.3 ± 13.0 0.6
BUN (mg/dL) 61.4 ± 20.7 60.2 ± 14.9 0.8 60.6 ± 16.8 68.1 ± 18.2 < 0.001
Creatinine (mg/dL) 9.1 ± 3.2 10.0 ± 3.1 0.4 9.8 ± 3.1 10.2 ± 3.4 0.2
Corrected serum calcium (mg/dL) 9.93 ± 0.91 9.27 ± 0.86 0.001 9.48 ± 0.93 9.22 ± 0.92 0.01
Phosphate (mg/dL) 5.47 ± 2.09 4.93 ± 1.47 0.3 5.09 ± 1.68 5.58 ± 1.57 0.007
iPTH (pg/mL)a 122 (45–319) 124 (45–202) 0.7 124 (45–202) 72 (28–155) 0.007
ALP (IU/L) 305 ± 103 285 ± 143 0.14 291 ± 131 282 ± 133 0.4
Serum albumin (g/dL) 3.41 ± 0.56 3.62 ± 0.50 0.07 3.55 ± 0.53 3.56 ± 0.43 0.9
CRP (mg/dL)a 0.39 (0.09–0.69) 0.17 (0.10–0.61) 0.3 0.20 (0.09–0.65) 0.18 (0.07–0.53) 0.2
T-Chol (mg/dL) 152 ± 35 156 ± 38 0.9 155 ± 37 162 ± 37 0.07
Triglyceride (mg/dL) 102 ± 60 89 ± 44 0.5 93 ± 49 106 ± 64 0.2
ADPKD autosomal dominant polycystic kidney disease, ALP alkaline phosphatase, BUN blood urea nitrogen, CERA continuous erythropoietin receptor activator, CRP
C-reactive protein, dBP diastolic blood pressure, dBP pre-HD diastolic blood pressure pre-hemodialysis, ESRD end-stage renal disease, HD hemodialysis, iPTH intact
parathyroid hormone, NIHSS National Institute of Health Stroke Scale, sBP systolic blood pressure, sBP pre-HD systolic blood pressure pre-hemodialysis, T-Chol total
cholesterol, TSAT transferrin saturation
Continuous variables are shown as mean ± standard deviation and categorical variables, as percentage or number (percentage)
a Median (interquartile range)
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verity of cerebral hemorrhage. The corrected serum cal-
cium had the greatest effect on cerebral hemorrhage
among them (P < 0.001) (Table 3).
Differences between cerebral hemorrhage group and
control group
As shown in Table 2 (right side), significant differences
were noted in the dialyzing time, BP pre-HD, proportion of
online hemodiafiltration (HDF), erythropoiesis-stimulating
agent (ESA) doses, ferritin levels, blood urea nitrogen
(BUN) levels, corrected serum calcium levels, serum phos-
phate levels, and iPTH between cerebral hemorrhage group
and control group.
The univariate logistic regression model was applied to
these factors and the predetermined traditional risk factors,
and multivariable logistic regression analysis was performed
subsequently. Model 1 was composed of risk factors for
traditional cerebral hemorrhage, and model 2 was created
by stepwise methods. Although sBP pre-HD had the great-
est association with cerebral hemorrhage in both models,
the corrected serum calcium and iPTH were also signifi-
cant parameters for cerebral hemorrhage (Table 4).
Predictors of hematoma volume
To determine the predictors and identify the relation-
ship between the corrected serum calcium level and
hematoma volume, multiple regression analysis was
performed. Model 1 consisted of predetermined fac-
tors, and model 2 included use of antiplatelet in
addition to the model 1 factors. Multiple regression
analysis indicated that the size of the hematoma was sig-
nificantly correlated with the corrected serum calciumlevel (β 0.378; standard error (SE) 0.101; P < 0.001) and
antiplatelet use (β 0.378; SE 0.089; P = 0.005) (model 2;
R2 = 0.26); however, sBP pre-HD proximate to the onset
had no significant correlation with hematoma volume
(P = 0.09) (Table 5).
Neurological prognosis and corrected serum calcium level
To elucidate the corrected serum calcium levels and
neurological prognoses of cerebral hemorrhage, the pa-
tients with cerebral hemorrhage were divided into four
groups according to the corrected serum calcium levels
(Q1–Q4): Q1 (corrected serum calcium ≤8.8 mg/dL), Q2
(8.9–9.5 mg/dL), Q3 (9.6–10.1 mg/dL), and Q4 (≥10.2
mg/dL), and the severity of ADL (mRS) was analyzed.
The proportions of patients with severe cerebral
hemorrhage, who were mRS5 (severe disabled, bed rid-
den) and mRS 6 (in-hospital death) were as follows: Q1,
57%; Q2, 63%; Q3, 67%; and Q4, 83% (Fig. 3). In addition
to patients who died and those who survived, the sever-
ity of ADL (mRS) at discharge was also significantly as-
sociated with high calcium levels (P = 0.02 by Cochran-
Armitage test).
Correlation between serum calcium levels and factors
that could affect serum calcium levels in patients with
cerebral hemorrhage
We attempted to elucidate factors that affected the serum
calcium levels in patients with cerebral hemorrhage as fol-
lows: serum phosphate level, iPTH level, serum alkaline
phosphatase (ALP) level, vitamin D, cinacalcet, calcium bi-
carbonate, dialysate calcium level, and before onset ADLs
(cut-off point was mRS 3; mRS ≤3 could walk independ-




Fig. 2 Characteristics of patients with hematoma. a Location of hematoma. b Distribution of hematoma volume. c Neurological severity
outcomes, as a severity of cerebral hemorrhage. The numbers in these figures represent the numbers of patients
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Table 3 Univariate and multivariate logistic regression analyses for prognosis
Univariate Model 1 Model 2
OR 95% CI P value OR 95% CI P value OR 95% CI P value
Age per year 1.00 0.96–1.04 0.9 1.00 0.96–1.05 0.9
Male vs. female 0.76 0.31–1.84 0.5 0.88 0.34–2.32 0.8
Dialysis vintage 1.00 0.95–1.07 0.8
History of diabetes 1.33 0.56–3.14 0.5
Ischemic heart disease 5.33 1.75–16.2 0.002
Heart valve repair or replacement 12.0 1.34–108 0.03 32.4 2.61–403 0.007
Antiplatelet use 3.26 1.34–7.93 0.008 4.30 1.52–12.2 0.006
Warfarin use 4.13 1.23–13.9 0.02
sBP pre-HD proximate the onset per 10 mmHg 1.04 0.92–1.18 0.5
Corrected serum calcium per mg/dL 2.38 1.39–4.09 < 0.001 2.37 1.42–4.23 < 0.001 2.91 1.58–5.35 < 0.001
Phosphate per mg/dL 1.21 0.93–1.58 0.2
iPTH per 10 pg/mL 1.01 0.97–1.05 0.7
Serum albumin per g/dL 0.46 0.20–1.05 0.06
CI confidential interval, OR odds ratio
Model 1: including age, sex, and corrected serum calcium
Model 2: including repair and/or replacement, antiplatelet use, and corrected serum calcium. Valve repair and/or replacement and antiplatelet use were selected
by the stepwise method (mixed method)
Table 4 Univariate and multivariate logistic regression analyses for the onset of cerebral hemorrhage
Univariate Model 1 Model 2
OR 95% CI P value OR 95% CI P value OR 95% CI P value
Age per year 0.98 0.97–1.00 0.08 0.99 0.97–1.02 0.5
Male vs. female 1.49 0.93–2.39 0.09 1.63 0.86–3.11 0.1
HD vintage per year 1.02 0.99–1.05 0.14 1.02 0.98–1.07 0.3
History of diabetes 1.22 0.77–1.95 0.4 1.01 0.51–2.01 0.9
Number of antihypertensive drugs 1.09 0.93–1.27 0.3
Warfarin use 1.98 0.97–4.05 0.07 1.45 0.48–4.41 0.5
Dialyzing time per hour 1.54 1.05–2.23 0.03 1.55 0.95–2.52 0.08
Online HDF 0.36 0.17–0.74 0.002 0.42 0.17–1.01 0.052
ESA per 100 U 1.00 1.00–1.01 0.07 1.00 1.00–1.01 0.5
Intravenous Fe 1.61 0.95–2.70 0.07 1.60 0.81–3.22 0.2
sBP pre-HD per 10 mmHg 1.33 1.21–1.47 < 0.001 1.41 1.23–1.61 < 0.001 1.40 1.23–1.59 < 0.001
Hb per g/dL 0.88 0.75–1.04 0.13 0.82 0.66–1.02 0.07
Ferritin per 10 ng/mL 1.01 1.00–1.02 0.2
BUN per 10 mg/dL 0.79 0.70–0.90 < 0.001 0.85 0.71–1.01 0.06
Corrected serum calcium per mg/dL 1.40 1.07–1.83 0.01 1.52 1.05–2.20 0.03 1.54 1.07–2.22 0.02
Phosphate per mg/dL 0.82 0.70–0.95 0.007 0.81 0.66–0.98 0.03 0.86 0.71–1.05 0.1
iPTH per 10 pg/mL 1.02 1.01–1.04 0.02 1.03 1.00–1.05 0.03 1.03 1.01–1.05 0.02
T-Chol per 10 mg/dL 0.95 0.89–1.01 0.12
BUN blood urea nitrogen, CI confidential interval, ESA erythropoiesis-stimulating agent, HD hemodialysis, HDF hemodiafiltration, iPTH intact parathyroid hormone,
OR odds ratio, sBP pre-HD systolic blood pressure pre-hemodialysis
Model 1: Adjusted by age and sex
Model 2: Adjusted by corrected serum calcium, dialyzing time, online hemodiafiltration, sBP pre-HD, BUN, phosphate, iPTH (parameters were selected by the
stepwise method (mixed method))
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Table 5 Multiple linear regression analysis model for hematoma volume (logarithmic converted)
Model 1 Model 2
β Standard Error P value β Standard Error P value
Age (year) 0.011 0.008 0.2 0.007 0.008 0.4
Female −0.031 0.086 0.7 −0.013 0.089 0.9
sBP pre-HD proximate the onset(/mmHg) 0.007 0.003 0.08 0.006 0.003 0.09
Corrected serum calcium (mg/dL) 0.381 0.093 0.02 0.378 0.101 < 0.001
Antiplatelet use 0.24 0.089 0.005
R2 0.17 0.26
dBP pre-HD diastolic pressure pre-hemodialysis, iPTH intact parathyroid hormone, sBP pre-HD systolic blood pressure pre-hemodialysis
Model 1: including age, sex, sBP pre-HD proximate the onset, corrected serum calcium
Model 2: in addition to the model 1’s parameter, antiplatelet use was selected by stepwise method (mixed method)
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served in the serum calcium levels and any of the men-
tioned factors (Additional file 1 Table 1).Discussion
To our knowledge, this is the first study to elucidate the as-
sociation between serum calcium and cerebral hemorrhage
in patients on HD. The corrected serum calcium was posi-
tively correlated with the prognosis: disabilities and death
from cerebral hemorrhage, hematoma volume, and onset of
cerebral hemorrhage in HD patients. After cerebral
hemorrhage, more than half of the patients were bedridden
or dead (Fig. 3), and the occurrence of cerebral hemorrhage
in HD patients should be reduced.Fig. 3 Distribution on the modified Rankin scale score at discharge by the
proportions of patients according to the modified Rankin scale. mRS: modiAccording to previous studies [9, 12], no significant
association was found between serum calcium and cere-
bral hemorrhage; however, data proximate to the cere-
bral hemorrhage onset were not available in these
studies. In our study, serum calcium values were col-
lected close to onset of cerebral hemorrhage and were
associated with the prognosis and deterioration of ADL
after cerebral hemorrhage (Table 2, Fig. 3). Although
precise ADL levels before onset could not be evaluated
in the cerebral hemorrhage group, the proportion of
walking independently in this group was not very low
(Table 2). In this study, the higher the serum calcium level,
the lower the ADL after cerebral hemorrhage (Fig. 3).
In the general population, a lower serum calcium level
is inversely associated with hematoma volume and poorquartile of the corrected serum calcium. Numbers represent the
fied Rankin Scale
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hospital death in patients whose corrected serum cal-
cium were < 8.4 mg/dL, suggesting that there was no U-
shaped or J-shaped phenomenon between the serum cal-
cium and cerebral hemorrhage in HD patients. Although
our analyses could not establish the precise relationship be-
tween the serum calcium level and cerebral hemorrhage,
several possible mechanisms may explain it. First, a high
serum calcium level is associated with fragile arteries due to
vascular calcification [28]. Second, changes in calcium
homeostasis may affect the vascular tone [29] and function
of the blood–brain barrier [30]. Calcium may alter the in-
tegrity of blood–brain barrier via several molecular mecha-
nisms and direct interaction of calcium ions with junctional
proteins [30]. Unlike the general population, the serum cal-
cium level transition during HD should be considered in
these patients [31]. Lowering the calcium concentration in
the dialysate is associated with cardiovascular instability
and arrhythmias [32]; therefore, the use of low calcium
concentration dialysate for calcium reduction was not rec-
ommended [33]. From these points of view, calcium con-
centration transition might be associated with cerebral
hemorrhage. Third, the possibility that patients with high
serum calcium level had low serum albumin and ADL
levels cannot be excluded. We could not adjust the pre-
onset ADL levels, which may affect the ADL after cerebral
hemorrhage (Fig. 3).
In this study, more than half of patients in the cerebral
hemorrhage and control groups were prescribed vitamin
D. As vitamin D increases the serum calcium level, it is
not advisable to use vitamin D for secondary hyperpara-
thyroidism routinely [16]. Recently, calcimimetics, such
as cinacalcet and etelcalcetide, have been widely used for
secondary hyperparathyroidism [34], and they can be
considered as the first-choice treatment for secondary
hyperparathyroidism instead of vitamin D. However, a
low serum calcium level is a risk factor for adverse ef-
fect, such as sudden death due to arrhythmia, then
serum calcium monitoring is needed.
Based on previous reports in the general population,
antiplatelet therapy was proven to be associated with a sig-
nificantly increased risk of cerebral hemorrhage [35], subse-
quent poor prognosis [36], and early hematoma growth [36];
a strong association was found between antiplatelet therapy
and a poor outcome and hematoma volume in cerebral
hemorrhage. Therefore, HD patients prescribed antiplatelets
should be monitored for occurrence of bleeding.
This study has some limitations. Its generalizability
may be limited by its retrospective study design. The
study was conducted in Nagasaki area, which might
make generalization of the present results to other re-
gions difficult. The number of outcomes and patients
were not enough to adjust for confounding factors. In-
formation bias, especially in past histories ofcomplications, could not be excluded. HD patients with
cerebral hemorrhage received treatment at several HD
centers; therefore, the treatment policies and modalities
differed among facilities, and interlaboratory discrepan-
cies in blood examinations cannot be excluded.
This study has several notable strengths. First, the de-
tails of patients with cerebral hemorrhage were available.
Data on the parameters were collected just before the
onset of cerebral hemorrhage, and data on detailed
neurological parameters, such as GCS, NIHSS, mRS,
and hematoma volume, were obtained after its onset,
unlike that in previous studies. Second, the number of
cases in this study was higher than those in previous
studies [2, 3, 7, 9–11]. The incidence of cerebral
hemorrhage was lower than that of other cardiovascular
complications in HD patients, so the numbers of cases
in previous studies was limited. Third, most HD patients
with cerebral hemorrhage in the Nagasaki City medical
zone, except cases of sudden death, were supposed to be
included during the observation period. The Nagasaki
City medical zone, surrounded by sea and hills, is geo-
graphically isolated. Nagasaki City and the neighboring
towns, Togitsu and Nagayo, are among the medical care
zone areas in Nagasaki prefecture, and their population
has been around 500,000 in the last 10 years; however,
the population of HD patients has increased slightly
from 1297 to 1464 between 2007 and 2016 [37]. Unlike
other facilities in the Nagasaki medical zone, Nagasaki
University Hospital has a stroke hotline and a HD cen-
ter; therefore, almost all HD patients with cerebral
hemorrhage were transferred to this hospital.
Conclusion
To prevent the onset and progression of cerebral
hemorrhage, serum calcium levels in HD patients should
be monitored. Further examinations of the direct rela-
tionship between high serum calcium concentrations
and cerebral hemorrhage in HD patients are warranted.
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